Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Cellect Biotechnology (APOP) Share Price
Headlines about Cellect Biotechnology (NASDAQ:APOP) have been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. Accern scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Cellect Biotechnology earned a news impact score of 0.17 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.8194972063818 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Cellect Biotechnology stock traded up $0.08 during trading hours on Wednesday, hitting $6.48. 4,733 shares of the stock traded hands, compared to its average volume of 94,992. The company has a market cap of $36.18, a PE ratio of -4.44 and a beta of 4.62. Cellect Biotechnology has a 1 year low of $6.12 and a 1 year high of $13.50.
Cellect Biotechnology (NASDAQ:APOP) last posted its quarterly earnings results on Monday, March 19th. The company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.31) by $0.15. analysts expect that Cellect Biotechnology will post -1.3 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Cellect Biotechnology (APOP) Share Price” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2018/04/25/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-cellect-biotechnology-apop-share-price.html.
About Cellect Biotechnology
Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.
Receive News & Ratings for Cellect Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellect Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.